TABLE 4

Summary of virus shedding (per-protocol population)a

CohortBaseline (day 1)Day 3Day 5Day 7Day 9Day 11Day 13
No. (%)Median (range)No. (%)Median (range)No. (%)Median (range)No. (%)Median (range)No. (%)Median (range)No. (%)Median (range)No. (%)Median (range)
Cohort 1:750 mg MEDI8852 + OS (n = 27)27 (100)6.38 (4.0–9.0)27 (100)4.91 (2.8–7.3)27 (100)2.80 (2.8–5.8)27 (100)2.80 (2.8–6.5)6 (22.2)2.80 (2.8–6.6)2 (7.4)2.80 (2.8–2.8)0 (0)NA
Cohort 2: 3,000 mg MEDI8852 + OS (n = 23)23 (100)7.26 (3.8–8.4)22 (95.7)5.08 (2.8–7.2)21 (91.3)2.80 (2.8–5.8)22 (95.7)2.80 (2.8–6.1)3 (13.0)2.80 (2.8–6.6)3 (13.0)2.80 (2.8–2.8)0 (0)NA
Cohort 3: placebo + OS (n = 30)30 (100)6.49 (2.8–8.7)29 (96.7)4.19 (2.8–8.1)28 (93.3)2.80 (2.8–6.1)30 (100)2.80 (2.8–4.8)7 (23.3)2.80 (2.8–5.0)3 (10.0)2.80 (2.8–2.8)0 (0)NA
Cohort 4 3,000 mg MEDI8852 (n = 24)24 (100)6.58 (3.2–8.1)23 (95.8)4.75 (2.8–7.9)24 (100)2.80 (2.8–7.0)23 (95.8)2.80 (2.8–5.0)7 (29.2)2.80 (2.8–2.8)4 (16.7)2.80 (2.8–4.1)1 (4.2)2.80 (2.8–2.8)
Cohorts 1, 2, and 4 combined: total MEDI8852 (n = 74)74 (100)6.88 (3.2–9.0)72 (97.3)4.86 (2.8–7.9)72 (97.3)2.80 (2.8–7.0)72 (97.3)2.80 (2.8–6.5)16 (21.6)2.80 (2.8–6.6)9 (12.2)2.80 (2.8–4.1)1 (1.4)2.80 (2.8–2.8)
  • a Virus titers were measured by qRT-PCR as log10 genome copies per ml. The LLOQ was log10 3.097 genome copies per ml. Samples determined to have virus titers greater than the LLOQ (log10 2.796 genome copies per ml) were reported as a value (genome copies per ml). Samples containing virus titers below the LLOQ were imputed to 0.5. NA, not applicable; OS, oseltamivir.